S&P 500   3,617.83 (-0.56%)
DOW   29,567.43 (-1.15%)
QQQ   299.60 (+0.20%)
AAPL   120.25 (+3.14%)
MSFT   212.85 (-1.11%)
FB   275.76 (-0.74%)
GOOGL   1,758.21 (-1.61%)
AMZN   3,167.34 (-0.88%)
TSLA   584.30 (-0.25%)
NVDA   531.54 (+0.21%)
BABA   264.49 (-4.34%)
CGC   29.01 (+0.03%)
GE   10.26 (-1.35%)
MU   64.41 (+0.28%)
AMD   91.95 (+5.46%)
T   28.79 (-0.83%)
NIO   51.84 (-4.00%)
F   9.11 (+0.22%)
ACB   11.85 (+13.18%)
NFLX   489.02 (-0.48%)
BA   211.91 (-2.12%)
GILD   59.84 (-0.32%)
DIS   147.92 (+0.54%)
S&P 500   3,617.83 (-0.56%)
DOW   29,567.43 (-1.15%)
QQQ   299.60 (+0.20%)
AAPL   120.25 (+3.14%)
MSFT   212.85 (-1.11%)
FB   275.76 (-0.74%)
GOOGL   1,758.21 (-1.61%)
AMZN   3,167.34 (-0.88%)
TSLA   584.30 (-0.25%)
NVDA   531.54 (+0.21%)
BABA   264.49 (-4.34%)
CGC   29.01 (+0.03%)
GE   10.26 (-1.35%)
MU   64.41 (+0.28%)
AMD   91.95 (+5.46%)
T   28.79 (-0.83%)
NIO   51.84 (-4.00%)
F   9.11 (+0.22%)
ACB   11.85 (+13.18%)
NFLX   489.02 (-0.48%)
BA   211.91 (-2.12%)
GILD   59.84 (-0.32%)
DIS   147.92 (+0.54%)
S&P 500   3,617.83 (-0.56%)
DOW   29,567.43 (-1.15%)
QQQ   299.60 (+0.20%)
AAPL   120.25 (+3.14%)
MSFT   212.85 (-1.11%)
FB   275.76 (-0.74%)
GOOGL   1,758.21 (-1.61%)
AMZN   3,167.34 (-0.88%)
TSLA   584.30 (-0.25%)
NVDA   531.54 (+0.21%)
BABA   264.49 (-4.34%)
CGC   29.01 (+0.03%)
GE   10.26 (-1.35%)
MU   64.41 (+0.28%)
AMD   91.95 (+5.46%)
T   28.79 (-0.83%)
NIO   51.84 (-4.00%)
F   9.11 (+0.22%)
ACB   11.85 (+13.18%)
NFLX   489.02 (-0.48%)
BA   211.91 (-2.12%)
GILD   59.84 (-0.32%)
DIS   147.92 (+0.54%)
S&P 500   3,617.83 (-0.56%)
DOW   29,567.43 (-1.15%)
QQQ   299.60 (+0.20%)
AAPL   120.25 (+3.14%)
MSFT   212.85 (-1.11%)
FB   275.76 (-0.74%)
GOOGL   1,758.21 (-1.61%)
AMZN   3,167.34 (-0.88%)
TSLA   584.30 (-0.25%)
NVDA   531.54 (+0.21%)
BABA   264.49 (-4.34%)
CGC   29.01 (+0.03%)
GE   10.26 (-1.35%)
MU   64.41 (+0.28%)
AMD   91.95 (+5.46%)
T   28.79 (-0.83%)
NIO   51.84 (-4.00%)
F   9.11 (+0.22%)
ACB   11.85 (+13.18%)
NFLX   489.02 (-0.48%)
BA   211.91 (-2.12%)
GILD   59.84 (-0.32%)
DIS   147.92 (+0.54%)
Log in
NASDAQ:IDXX

IDEXX Laboratories Stock Forecast, Price & News

$456.84
+2.61 (+0.57 %)
(As of 11/30/2020 03:00 PM ET)
Add
Compare
Today's Range
$451.93
Now: $456.84
$458.63
50-Day Range
$393.51
MA: $438.57
$478.10
52-Week Range
$168.65
Now: $456.84
$485.00
Volume9,438 shs
Average Volume539,620 shs
Market Capitalization$38.97 billion
P/E Ratio79.59
Dividend YieldN/A
Beta0.9
IDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers that are used in the human point-of-care medical diagnostics market. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Read More
IDEXX Laboratories logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.46 out of 5 stars


Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:IDXX
CUSIP45168D10
Phone207-556-0300
Employees9,200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.41 billion
Cash Flow$5.85 per share
Book Value$5.17 per share

Profitability

Net Income$427.72 million

Miscellaneous

Market Cap$38.97 billion
Next Earnings Date1/29/2021 (Estimated)
OptionableOptionable
$456.84
+2.61 (+0.57 %)
(As of 11/30/2020 03:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IDXX News and Ratings via Email

Sign-up to receive the latest news and ratings for IDXX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











IDEXX Laboratories (NASDAQ:IDXX) Frequently Asked Questions

How has IDEXX Laboratories' stock price been impacted by COVID-19?

IDEXX Laboratories' stock was trading at $245.58 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, IDXX shares have increased by 85.6% and is now trading at $455.80.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of IDEXX Laboratories?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for IDEXX Laboratories
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than IDEXX Laboratories?

Wall Street analysts have given IDEXX Laboratories a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but IDEXX Laboratories wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is IDEXX Laboratories' next earnings date?

IDEXX Laboratories is scheduled to release its next quarterly earnings announcement on Friday, January 29th 2021.
View our earnings forecast for IDEXX Laboratories
.

How were IDEXX Laboratories' earnings last quarter?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) announced its quarterly earnings data on Thursday, October, 29th. The company reported $1.69 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $1.42 by $0.27. The business had revenue of $721.79 million for the quarter, compared to analyst estimates of $672.48 million. IDEXX Laboratories had a return on equity of 198.91% and a net margin of 19.20%. IDEXX Laboratories's revenue for the quarter was up 19.2% compared to the same quarter last year. During the same period last year, the firm earned $1.24 EPS.
View IDEXX Laboratories' earnings history
.

How will IDEXX Laboratories' stock buyback program work?

IDEXX Laboratories announced that its board has authorized a stock repurchase program on Wednesday, February 12th 2020, which permits the company to repurchase 5,000,000 outstanding shares, according to EventVestor. This repurchase authorization permits the company to purchase shares of its stock through open market purchases. Stock repurchase programs are often an indication that the company's board of directors believes its shares are undervalued.

What price target have analysts set for IDXX?

3 brokers have issued 1 year target prices for IDEXX Laboratories' shares. Their forecasts range from $375.00 to $422.00. On average, they expect IDEXX Laboratories' share price to reach $395.67 in the next twelve months. This suggests that the stock has a possible downside of 13.2%.
View analysts' price targets for IDEXX Laboratories
.

Are investors shorting IDEXX Laboratories?

IDEXX Laboratories saw a decline in short interest in October. As of October 30th, there was short interest totaling 919,200 shares, a decline of 19.4% from the October 15th total of 1,140,000 shares. Based on an average daily volume of 422,100 shares, the short-interest ratio is presently 2.2 days. Approximately 1.1% of the company's stock are sold short.
View IDEXX Laboratories' Short Interest
.

Who are some of IDEXX Laboratories' key competitors?

What other stocks do shareholders of IDEXX Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Netflix (NFLX), PayPal (PYPL), Mastercard (MA), Adobe (ADBE), Tesla (TSLA), Alibaba Group (BABA), Square (SQ), The Walt Disney (DIS) and Shopify (SHOP).

Who are IDEXX Laboratories' key executives?

IDEXX Laboratories' management team includes the following people:
  • Mr. Jonathan J. Mazelsky, Pres, CEO & Director (Age 59, Pay $1.62M)
  • Ms. Sharon E. Underberg, Exec. VP, CFO & Treasurer (Age 59, Pay $809.42k)
  • Ms. Kathy V. Turner, Chief Marketing Officer & Corp. VP (Age 56, Pay $1.95M)
  • Mr. Jonathan W. Ayers, Sr. Advisor & Director (Age 64, Pay $3.2M)
  • Mr. Michael J. Lane, Exec. VP and GM of Reference Laboratories & Information Technology (Age 52, Pay $724.02k)
  • Mr. John Hart, Corp. VP of Worldwide Operations
  • Mr. Jeffery D. Chadbourne, Sr. Director of Accounting & Financial Reporting (Age 44)
  • Mr. Jeffrey Thomas, Corp. VP & Chief Technology Officer
  • Mr. Ken Grady, Corp. VP & Chief Information Officer
  • Ms. Kerry Bennett, VP of Investor Relations

What is IDEXX Laboratories' stock symbol?

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

Who are IDEXX Laboratories' major shareholders?

IDEXX Laboratories' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.10%), State Street Corp (4.31%), Blair William & Co. IL (1.77%), Principal Financial Group Inc. (1.39%), Neuberger Berman Group LLC (1.29%) and Nuveen Asset Management LLC (0.73%). Company insiders that own IDEXX Laboratories stock include Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, Jacqueline Studer, James F Polewaczyk, Jay Mazelsky, Jonathan Jay Mazelsky, Jonathan W Ayers, Lawrence D Kingsley, M Anne Szostak, Michael Lane, Nimrata Hunt, Rebecca M Henderson and Sophie V Vandebroek.
View institutional ownership trends for IDEXX Laboratories
.

Which major investors are selling IDEXX Laboratories stock?

IDXX stock was sold by a variety of institutional investors in the last quarter, including Durable Capital Partners LP, State Street Corp, Principal Financial Group Inc., Arrowstreet Capital Limited Partnership, JPMorgan Chase & Co., Wells Fargo & Company MN, New York State Common Retirement Fund, and Blair William & Co. IL. Company insiders that have sold IDEXX Laboratories company stock in the last year include Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, James F Polewaczyk, Jonathan Jay Mazelsky, Jonathan W Ayers, M Anne Szostak, Michael Lane, Nimrata Hunt, and Rebecca M Henderson.
View insider buying and selling activity for IDEXX Laboratories
.

Which major investors are buying IDEXX Laboratories stock?

IDXX stock was purchased by a variety of institutional investors in the last quarter, including CIBC Private Wealth Group LLC, BlackRock Inc., Natixis, Los Angeles Capital Management & Equity Research Inc., Skandinaviska Enskilda Banken AB publ, Nisa Investment Advisors LLC, WCM Investment Management LLC, and Charles Schwab Investment Management Inc..
View insider buying and selling activity for IDEXX Laboratories
.

How do I buy shares of IDEXX Laboratories?

Shares of IDXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is IDEXX Laboratories' stock price today?

One share of IDXX stock can currently be purchased for approximately $455.80.

How big of a company is IDEXX Laboratories?

IDEXX Laboratories has a market capitalization of $38.88 billion and generates $2.41 billion in revenue each year. The company earns $427.72 million in net income (profit) each year or $4.89 on an earnings per share basis. IDEXX Laboratories employs 9,200 workers across the globe.

What is IDEXX Laboratories' official website?

The official website for IDEXX Laboratories is www.idexx.com.

How can I contact IDEXX Laboratories?

IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company can be reached via phone at 207-556-0300 or via email at [email protected]

This page was last updated on 11/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.